S49 - MS Epidemiology and Risk Stratification
| Event Time: | Thursday May 9, 2019 1:00 pm to 3:00 pm |
| Topic(s): | MS and CNS Inflammatory Disease |
| Director(s): | |
| Description: | |
| Completion Message: | |
| CME Credits: | 2 |
| Core Competencies: |
| Start/End Time | Title | Faculty |
|---|---|---|
| 2:40 PM - 3:00 PM | Q&A Panel with Authors | Faculty |
| Speaker | Disclosure |
|---|
| Start Time | Pub. | Title | Presenter |
|---|---|---|---|
| 1:00 PM | 001 | Multiple sclerosis genetic risk burden confers earlier onset. |
Disclosure: Dr. Briggs has nothing to disclose.
|
| 1:00 PM | 002 | The Relationship between Obstructive Sleep Apnea and Age, Gender, EDSS, Disease Duration, and BMI in People with Multiple Sclerosis Who Report Fatigue: More than Size Matters |
Disclosure: Dr. Cascone has nothing to disclose.
|
| 1:00 PM | 003 | Amyloid PET in multiple sclerosis predicts cognitive decline at 18 months |
Disclosure: Dr. Matias-Guiu has nothing to disclose.
|
| 1:00 PM | 004 | Structural and Functional Damage of the Sensorimotor Network Contribute to Predict Disability Progression and Phenotype Evolution in Patients with Multiple Sclerosis: A 6.5-Year Follow-Up Study |
Disclosure: Dr. Filippi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Merk-Serono, Novartis, Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in an editorial capacity for Journal of Neurology. Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Teva Pharmaceutical Industries, Roche.
|
| 1:00 PM | 005 | Pregnancy and Infant Outcomes with Interferon Beta: Data from the European Interferon Beta Pregnancy Registry and MS Preg study conducted in Finland and Sweden |
Disclosure: Dr. Hellwig has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer, Biogen, Sanofi, Teva, Roche, Novartis, Merck. Dr. Hellwig has received research support from Bayer, Biogen, Merck, Novartis, Sanofi, Genzyme, Teva.
|
| 1:00 PM | 006 | Executive Control of Attention Predicts Risk for Future Depression in Early Multiple Sclerosis |
Disclosure: Dr. Glukhovsky has nothing to disclose.
|
| 1:00 PM | 007 | Early Life Nutrition and Risk of Pediatric Multiple Sclerosis |
Disclosure: Dr. Gambrah Sampaney has nothing to disclose.
|
| 1:00 PM | 008 | Pediatric multiple sclerosis severity score in a large U.S. cohort |
Disclosure: Dr. Santoro has nothing to disclose.
|
| 1:00 PM | 009 | Assessment of Baseline Imaging Features as Predictors of Poor Disease Course in Pediatric Onset Multiple Sclerosis |
Disclosure: Dr. Brown has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen IDEC, NeuroRX.
|
Ready to register for the 2019 AAN Annual Meeting?
Related Courses
| 7:00 AM-9:00 AM |
|---|
|
C7 -
Clinical Pearls in Autoimmune Neurology: Real World Cases
Stacey Clardy MD, PhD |
| 9:30 AM-11:30 AM |
|
C19 -
Multiple Sclerosis Overview I: Clinical Pearls
Mary Willis MD |
| 1:30 PM-3:30 PM |
|
C29 -
Multiple Sclerosis Overview II: Clinical Advances
Scott Newsome DO, FAAN |
| 7:00 AM-9:00 AM |
|---|
|
C44 -
Multiple Sclerosis Therapy: Symptom Management
Andrew Solomon MD, FAAN |
| 9:15 AM-12:00 PM |
|
Presidential Plenary Session
Natalia Rost MD, MPH, FAAN, FAHA |
| 11:30 AM-6:30 PM |
|
P1 -
Poster Session 1
|
| 1:00 PM-3:00 PM |
|
C49 -
Neurology Update I: Multiple Sclerosis, Sleep, and Neuromuscular Disease
Ralph Jozefowicz MD, FAAN, Adam Quick MD |
|
C56 -
Multiple Sclerosis Therapy: Disease-modifying Treatment I
Scott Newsome DO, FAAN |
|
S6 -
MS and CNS Inflammatory Disease: Clinical Considerations I
|
| 3:30 PM-5:30 PM |
|
C73 -
Multiple Sclerosis Therapy: Disease-modifying Treatment II
John Rose MD, FAAN |
| 7:00 AM-9:00 AM |
|---|
|
C86 -
Neuromyelitis Optica Spectrum Disorders
Dean Wingerchuk MD, FAAN |
| 9:15 AM-12:00 PM |
|
Contemporary Clinical Issues Plenary Session
Randolph Marshall MD, FAAN |
| 11:30 AM-6:30 PM |
|
P2 -
Poster Session 2
|
| 1:00 PM-3:00 PM |
|
C100 -
Esclerosis Múltiple y Otras Enfermedades Inflamatorias Desmielinizantes y Autoinmunes del Sistema Nervioso Central (MS and Other Demyelinating Inflammatory and Autoimmune Central Nervous System Disorders)
Lilyana Amezcua MD, FAAN |
|
S12 -
Progressive Multiple Sclerosis
|
| 3:30 PM-5:30 PM |
|
S19 -
Child Neurology: Updates in Autism, Migraine, MS, and Stroke
|
| 7:00 AM-9:00 AM |
|---|
|
C130 -
Diagnostic Pearls in Myelitis: a Case-based Approach
Eoin Flanagan MBBCh |
| 9:15 AM-11:30 AM |
|
Clinical Trials Plenary Session
Deborah Hall MD, PhD, FAAN, Holly Hinson MD, MCR, FAAN |
| 11:30 AM-6:30 PM |
|
P3 -
Poster Session 3
|
| 1:00 PM-3:00 PM |
|
C142 -
Autoimmune Neurology I Basics and Beyond: Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes of the CNS and PNS
Stacey Clardy MD, PhD |
|
N3 -
Neuroscience in the Clinic: Stem Cells
Paul George MD, PhD, MSE, Antonio Omuro MD |
|
S26 -
MS and CNS Inflammatory Disease: Clinical Considerations II
|
| 3:30 PM-5:30 PM |
|
C160 -
Autoimmune Neurology II Advanced: Autoimmune Encephalitis at the Frontiers of Neuroscience
Eoin Flanagan MBBCh |
|
S31 -
MS and CNS Inflammatory Disease: Imaging
|
| 9:15 AM-11:30 AM |
|---|
|
Frontiers in Neuroscience Plenary Session
Paul George MD, PhD, MSE |
| 11:30 AM-6:30 PM |
|
P4 -
Poster Session 4
|
| 1:00 PM-3:00 PM |
|
C181 -
Treatment of Pediatric Multiple Sclerosis in the Current Era
Brenda Banwell MD, FAAN |
|
S37 -
MS Biomarkers
|
| 3:30 PM-5:30 PM |
|
Presentation of the John Dystel Prize for Multiple Sclerosis Research
|
| 3:45 PM-4:15 PM |
|
Update on the Complementary Therapies for MS: An Evidence-based Review
Vijayshree Yadav MD, FAAN |
| 11:30 AM-6:30 PM |
|---|
|
P5 -
Poster Session 5
|
| 12:00 PM-12:45 PM |
|
A "How to and Why" of the Shared Medical Appointments: A Way to Meet the Needs of the Patient and Provider While Maximizing Clinical Time
Mary Rensel MD, FAAN, Nancy Isenberg MD, MPH, FAAN |
| 1:00 PM-3:00 PM |
|
C226 -
Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease I
Jeffrey Gelfand MD, MAS, FAAN |
| 3:30 PM-5:30 PM |
|
C236 -
Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease II
Jeffrey Gelfand MD, MAS, FAAN |
|
S55 -
MS Basic Science
|
| 7:00 AM-9:00 AM |
|---|
|
C248 -
Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making
Aaron Miller MD, FAAN |
| 9:15 AM-11:30 AM |
|
Neurology Year in Review Plenary Session
Martinson Arnan MD |
| 1:00 PM-3:00 PM |
|
S56 -
MS Trials and Treatment
|
| 3:30 PM-4:30 PM |
|
C257 -
Education Blitz: Evolution of Autoimmune Neurology
Steven Vernino MD, PhD, FAAN |
|
C258 -
Education Blitz: Multiple Sclerosis
Stephen Krieger MD, FAAN |